News for Healthier Living

Despite Its Efficacy, Efanesoctocog Alfa Not a Cost-Effective Choice in Treating Severe Hemophilia A

A cost-effectiveness analysis evaluated whether a newer and more efficacious treatment to prevent bleeding in those with severe hemophilia A, efanesoctocog alfa (Altuviiio), improves outcomes enough to justify its higher cost compared to standard-care factor VIII prophylaxis.

April 21, 2025


April 23 2025

April 22 2025

April 21 2025

April 19 2025

April 18 2025

April 17 2025

April 16 2025

April 15 2025

April 14 2025

April 12 2025

April 11 2025

April 10 2025

April 9 2025